Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
Article Sidebar
Main Article Content
Abstract
This review focuses on the use of chimeric antigen receptor (CAR)-T cell therapy to treat non-Hodgkin’s lymphoma (NHL), a classification of heterogeneous malignant neoplasms of the lymphoid tissue. Despite various conventional and multidrug chemotherapies, the poor prognosis for NHL patients remains and has prompted the utilization of groundbreaking personalized therapies such as CAR-T cells. CAR-T cells are T cells engineered to express a CAR that enables T cells to specifically lyse tumor cells with extracellular expression of a tumor antigen of choice. A CAR is composed of an extracellular antibody fragment or target protein binding domain that is conjugated to activating intracellular signaling motifs common to T cells. In general, CAR-T cell therapies for NHL are designed to recognize cellular markers ubiquitously expressed on B cells such as CD19+, CD20+, and CD22+. Clinical trials using CAR-T cells such as ZUMA-7 and TRANSFORM demonstrated promising results compared to standard of care and ultimately led to FDA approval for the treatment of relapsed/refractory NHL. Despite the success of CAR-T therapy for NHL, challenges include adverse side effects as well as extrinsic and intrinsic mechanisms of tumor resistance that lead to suboptimal outcomes. Overall, CAR-T cell therapies have improved clinical outcomes in NHL patients and generated optimism around their future applications.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. Sapkota S, Shaikh H. Non-Hodgkin Lymphoma. StatPearls. Treasure Island (FL)2022.
2. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin’s Lymphoma. Med Sci (Basel). 2021;9(1). doi: 10.3390/medsci9010005. PubMed PMID: 33573146; PMCID: PMC7930980.
3. Waits TM, Greco FA, Greer JP, Johnson DH, Wolff SN, Stein RS, McMaster ML, Hainsworth JD. Effective therapy for poor-prognosis non-Hodgkin’s lymphoma with 8 weeks of high-dose-intensity combination chemotherapy. J Clin Oncol. 1993;11(5):943-9. doi: 10.1200/JCO.1993.11.5.943. PubMed PMID: 7683712.
4. Cortelazzo S, Ponzoni M, Ferreri AJ, Dreyling M. Mantle cell lymphoma. Crit Rev Oncol Hematol. 2012;82(1):78-101. doi: 10.1016/j.critrevonc.2011.05.001. PubMed PMID: 21658968.
5. Ioannou N, Jain K, Ramsay AG. Immunomodulatory Drugs for the Treatment of B Cell Malignancies. Int J Mol Sci. 2021;22(16). doi: 10.3390/ijms22168572. PubMed PMID: 34445275; PMCID: PMC8395307.
6. Ansell SM, Lin Y. Immunotherapy of lymphomas. J Clin Invest. 2020;130(4):1576-85. doi: 10.1172/JCI129206. PubMed PMID: 32039913; PMCID: PMC7108914.
7. Valla K, Flowers CR, Koff JL. Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opin Investig Drugs. 2018;27(6):513-22. doi: 10.1080/13543784.2018.1482273. PubMed PMID: 29855199; PMCID: PMC6291828.
8. Motta G, Cea M, Moran E, Carbone F, Augusti V, Patrone F, Nencioni A. Monoclonal antibodies for non-Hodgkin’s lymphoma: state of the art and perspectives. Clin Dev Immunol. 2010;2010:428253. doi: 10.1155/2010/428253. PubMed PMID: 21437222; PMCID: PMC3061293.
9. Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019;16(8):494-507. doi: 10.1038/s41571-019-0190-8. PubMed PMID: 30837715; PMCID: PMC6650343.
10. Klanova M, Klener P. BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas. Cancers (Basel). 2020;12(4). doi: 10.3390/cancers12040938. PubMed PMID: 32290241; PMCID: PMC7226356.
11. Armengol M, Santos JC, Fernandez-Serrano M, Profitos-Peleja N, Ribeiro ML, Roue G. Immune-Checkpoint Inhibitors in B-Cell Lymphoma. Cancers (Basel). 2021;13(2). doi: 10.3390/cancers13020214. PubMed PMID: 33430146; PMCID: PMC7827333.
12. Srivastava S, Riddell SR. Engineering CAR-T cells: Design concepts. Trends Immunol. 2015;36(8):494-502. doi: 10.1016/j.it.2015.06.004. PubMed PMID: 26169254; PMCID: PMC4746114.
13. Marofi F, Rahman HS, Achmad MH, Sergeevna KN, Suksatan W, Abdelbasset WK, Mikhailova MV, Shomali N, Yazdanifar M, Hassanzadeh A, Ahmadi M, Motavalli R, Pathak Y, Izadi S, Jarahian M. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. Front Immunol. 2021;12:681984. doi: 10.3389/fimmu.2021.681984. PubMed PMID: 34248965; PMCID: PMC8261235.
14. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8. doi: 10.1182/blood-2017-03-769620. PubMed PMID: 28774879; PMCID: PMC5649550.
15. Jackson Z, Hong C, Schauner R, Dropulic B, Caimi PF, de Lima M, Giraudo MF, Gupta K, Reese JS, Hwang TH, Wald DN. Sequential single cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin’s lymphoma. Cancer Discov. 2022. doi: 10.1158/2159-8290.CD-21-1586. PubMed PMID: 35554512.
16. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci
U S A. 1989;86(24):10024-8.
17. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720-4. doi: 10.1073/pnas.90.2.720. PubMed PMID: 8421711; PMCID: PMC45737.
18. Uscanga-Palomeque AC, Chávez-Escamilla AK, Alvizo-Báez CA, Saavedra-Alonso S, Terrazas-Armendáriz LD, Tamez-Guerra RS, Rodríguez-Padilla C, Alcocer-González JM. CAR-T Cell Therapy: From the Shop to Cancer Therapy. Int J Mol Sci. 2023;24(21):15688. Published 2023 Oct 28: doi: 10.3390/ijms242115688.
19. Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049. Published 2023 May 15. doi: 10.3389/fimmu.2023.1188049.
20. Frederickson RM. A New Era of Innovation for CAR T-cell Therapy. Mol Ther. 2015;23(12):1795-6. doi: 10.1038/mt.2015.205.
21. Bourbon E, Ghesquières H, Bachy E. CAR-T cells, from principle to clinical applications. Bulletin du Cancer. 2021;108(10, Supplement):S4-S17. doi: 10.1016/j.bulcan.2021.02.017.
22. Janeway C. Immunobiology 5 : the immune system in health and disease. Fifth edition. ed. New York: Garland Pub.; 2001.
23. Park JH, Brentjens RJ. Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med. 2010;9(47):277-88. PubMed PMID: 20423671; PMCID: PMC4697441.
24. Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother. 2012;61(7):953-62. doi: 10.1007/s00262-012-1254-0. PubMed PMID: 22527245.
25. Zareie P, Szeto C, Farenc C, Gunasinghe SD, Kolawole EM, Nguyen A, Blyth C, Sng XYX, Li J, Jones CM, Fulcher AJ, Jacobs JR, Wei Q, Wojciech L, Petersen J, Gascoigne NRJ, Evavold BD, Gaus K, Gras S, Rossjohn J, La Gruta NL. Canonical T cell receptor docking on peptide-MHC is essential for T cell signaling. Science. 2021;372(6546). doi: 10.1126/science.abe9124. PubMed PMID: 34083463.
26. Maldini CR, Ellis GI, Riley JL. CAR T cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol. 2018;18(10):605-16. doi: 10.1038/s41577-018-0042-2. PubMed PMID: 30046149; PMCID: PMC6505691.
27. Cruz CR, Bollard CM. T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect. Haematologica. 2015;100(6):709-19. doi: 10.3324/haematol.2014.113860. PubMed PMID: 26034113; PMCID: PMC4450616.
28. Styczyński J. A brief history of CAR-T cells: from laboratory to the bedside. Acta Haematologica Polonica. 2020;51(1):2-5. doi: 10.2478/ahp-2020-0002.
29. Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomarker Research. 2017;5(1):22. doi: 10.1186/s40364-017-0102-y.
30. Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011;11(7):855-73. doi: 10.1517/14712598.2011.573476. PubMed PMID: 21463133; PMCID: PMC3107373.
31. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi: 10.1038/s41408-021-00459-7. PubMed PMID: 33824268; PMCID: PMC8024391.
32. Tomuleasa C, Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, Jurj A, Pop L, Berindan-Neagoe I, Dima D, Kitano S. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. Front Immunol. 2018;9:239. doi: 10.3389/fimmu.2018.00239. PubMed PMID: 29515572; PMCID: PMC5825894.
33. Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13(6):370-83. doi: 10.1038/nrclinonc.2016.36. PubMed PMID: 27000958;
PMCID: PMC5529102.
34. Liu J, Zhong JF, Zhang X, Zhang C. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017;10(1):35. doi: 10.1186/s13045-017-0405-3. PubMed PMID: 28143567; PMCID: PMC5282795.
35. Tasian SK, Gardner RA. CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol. 2015;6(5):228-41. doi: 10.1177/2040620715588916. PubMed PMID: 26425336; PMCID: PMC4556967.
36. Qu J, Mei Q, Chen L, Zhou J. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Cancer Immunol Immunother. 2021;70(3):619-31. doi: 10.1007/s00262-020-02735-0. PubMed PMID: 33025047; PMCID: PMC7907037.
37. Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181(5):1653-9. doi: 10.1084/jem.181.5.1653. PubMed PMID: 7722445; PMCID: PMC2192006.
38. Gandhi M, Jones K. Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients. Immunotherapy. 2011;3(12):1441-3. doi: 10.2217/imt.11.135. PubMed PMID: 22091680.
39. Oh I, Oh Y, Ohmine K. Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies. Rinsho Ketsueki. 2016;57(11):2365-72. doi: 10.11406/rinketsu.57.2365. PubMed PMID: 27941287.
40. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. PubMed PMID: 23546520; PMCID: PMC6322669.
41. Duan D, Wang K, Wei C, Feng D, Liu Y, He Q, Xu X, Wang C, Zhao S, Lv L, Long J, Lin D, Zhao A, Fang B, Jiang J, Tang S, Gao J. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma. Front Immunol. 2021;12:609421. doi: 10.3389/fimmu.2021.609421. PubMed PMID: 33767695; PMCID: PMC7985831.
42. Chmielewski M, Abken H. TRUCKS, the fourth-generation CAR T cells: Current developments and clinical translation. ADVANCES IN CELL AND GENE THERAPY. 2020;3(3):e84. doi: 10.1002/acg2.84.
43. Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol. 2022;13:927153. doi: 10.3389/fimmu.2022.927153. PubMed PMID: 35757715; PMCID: PMC9226391.
44. Feng DD, Chen XH, Guo JJ, Wang KK, Zhang XM, Gao JM. [Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma]. Zhonghua Zhong Liu Za Zhi. 2021;43(6):657-65. doi: 10.3760/cma.j.cn112152-20200415-00347. PubMed PMID: 34289557.
45. Zhou X, Di Stasi A, Brenner MK. iCaspase 9 Suicide Gene System. Methods Mol Biol. 2015;1317:87-105. doi: 10.1007/978-1-4939-2727-2_6. PubMed PMID: 26072403; PMCID: PMC4903016.
46. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Munoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR, All Z-I, Contributing Kite M. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640-54. doi: 10.1056/NEJMoa2116133. PubMed PMID: 34891224.
47. Roex G, Feys T, Beguin Y, Kerre T, Poire X, Lewalle P, Vandenberghe P, Bron D, Anguille S. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics. 2020;12(2). doi: 10.3390/pharmaceutics12020194. PubMed PMID: 32102267; PMCID: PMC7076393.
48. Meng J, Wu X, Sun Z, Xun R, Liu M, Hu R, Huang J. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis. Front Oncol. 2021;11:698607. doi: 10.3389/fonc.2021.698607. PubMed PMID: 34381720; PMCID: PMC8350577.
49. Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS, Investigators T. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294-308. doi: 10.1016/S0140-6736(22)00662-6. PubMed PMID: 35717989.
50. Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Muller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jager U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022;386(7):629-39. doi: 10.1056/NEJMoa2116596. PubMed PMID: 34904798.
51. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jager U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak O, Salles G, Maziarz RT, Investigators J. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56. doi: 10.1056/NEJMoa1804980. PubMed PMID: 30501490.
52. Siegler EL, Kenderian SS. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Front Immunol. 2020;11:1973. doi: 10.3389/fimmu.2020.01973. PubMed PMID: 32983132; PMCID: PMC7485001.
53. Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, Haris M, Wilson NE, Liu F, Gabunia K, Scholler J, Montine TJ, Bhoj VG, Reddy R, Mohan S, Maillard I, Kriegstein AR, June CH, Chang HY, Posey AD, Jr., Satpathy AT. Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell. 2020;183(1):126-42.e17. doi: 10.1016/j.cell.2020.08.022. PubMed PMID: 32961131; PMCID: PMC7640763.
54. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-17. doi: 10.1056/NEJMoa1407222. PubMed PMID: 25317870; PMCID: PMC4267531.
55. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372-85. doi: 10.1038/s41571-019-0184-6. PubMed PMID: 30837712; PMCID: PMC8214555.
56. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-28. doi: 10.1016/S0140-6736(14)61403-3. PubMed PMID: 25319501; PMCID: PMC7065359.
57. Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322-31. doi: 10.1182/blood-2017-02-769208. PubMed PMID: 28408462; PMCID: PMC5482103.
58. Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):449-59. doi: 10.1056/NEJMoa1709919. PubMed PMID: 29385376; PMCID: PMC6637939.
59. Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015;5(12):1282-95. doi: 10.1158/2159-8290.CD-15-1020. PubMed PMID: 26516065; PMCID: PMC4670800.
60. Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu MA, Kron B, Russo A, Lehmann N, Roth L, Fehr EM, Attig S, Hohberger A, Kindler T, Faber J. CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis. J Immunother. 2017;40(5):187-95. doi: 10.1097/CJI.0000000000000169. PubMed PMID: 28441264; PMCID: PMC5424577.
61. Braig F, Brandt A, Goebeler M, Tony HP, Kurze AK, Nollau P, Bumm T, Bottcher S, Bargou RC, Binder M. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2017;129(1):100-4. doi: 10.1182/blood-2016-05-718395. PubMed PMID: 27784674.
62. Qin H, Ramakrishna S, Nguyen S, Fountaine TJ, Ponduri A, Stetler-Stevenson M, Yuan CM, Haso W, Shern JF, Shah NN, Fry TJ. Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22. Mol Ther Oncolytics. 2018;11:127-37. doi: 10.1016/j.omto.2018.10.006. PubMed PMID: 30581986; PMCID: PMC6300726.
63. Schneider D, Xiong Y, Wu D, Hu P, Alabanza L, Steimle B, Mahmud H, Anthony-Gonda K, Krueger W, Zhu Z, Dimitrov DS, Orentas RJ, Dropulic B. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci Transl Med. 2021;13(586). doi: 10.1126/scitranslmed.abc6401. PubMed PMID: 33762438.
64. Enblad G, Karlsson H, Loskog AS. CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma. Hum Gene Ther. 2015;26(8):498-505. doi: 10.1089/hum.2015.054. PubMed PMID: 26230974; PMCID: PMC4554546.
65. Onea AS, Jazirehi AR. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphomas. Am J Cancer Res. 2016;6(2):403-24. PubMed PMID: 27186412; PMCID: PMC4859669.
66. Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 2015;36(4):229-39. doi: 10.1016/j.it.2015.02.004. PubMed PMID: 25770924.
67. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-74. doi: 10.1038/nri2506. PubMed PMID: 19197294; PMCID: PMC2828349.
68. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008;222:180-91. doi: 10.1111/j.1600-065X.2008.00608.x. PubMed PMID: 18364002; PMCID: PMC3546504.
69. Yeku OO, Brentjens RJ. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans. 2016;44(2):412-8. doi: 10.1042/BST20150291. PubMed PMID: 27068948; PMCID: PMC5529098.
70. Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH. Dominant-Negative TGF-beta Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Mol Ther. 2018;26(7):1855-66. doi: 10.1016/j.ymthe.2018.05.003. PubMed PMID: 29807781; PMCID: PMC6037129.
71. Titov A, Kaminskiy Y, Ganeeva I, Zmievskaya E, Valiullina A, Rakhmatullina A, Petukhov A, Miftakhova R, Rizvanov A, Bulatov E. Knowns and Unknowns about CAR-T Cell Dysfunction. Cancers (Basel). 2022;14(4). doi: 10.3390/cancers14041078. PubMed PMID: 35205827; PMCID: PMC8870103.
72. Kasakovski D, Xu L, Li Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies. J Hematol Oncol. 2018;11(1):91. doi: 10.1186/s13045-018-0629-x. PubMed PMID: 29973238; PMCID: PMC6032767.
73. Mou D, Espinosa J, Lo DJ, Kirk AD. CD28 negative T cells: is their loss our gain? Am J Transplant. 2014;14(11):2460-6. doi: 10.1111/ajt.12937. PubMed PMID: 25323029; PMCID: PMC4886707.
74. Burugu S, Dancsok AR, Nielsen TO. Emerging targets in cancer immunotherapy.
Semin Cancer Biol. 2018;52(Pt 2):39-52. doi: 10.1016/j.semcancer.2017.10.001. PubMed PMID: 28987965.
75. Kared H, Martelli S, Ng TP, Pender SL, Larbi A. CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother. 2016;65(4):441-52. doi: 10.1007/s00262-016-1803-z. PubMed PMID: 26850637.
76. Kalinin RS, Ukrainskaya VM, Chumakov SP, Moysenovich AM, Tereshchuk VM, Volkov DV, Pershin DS, Maksimov EG, Zhang H, Maschan MA, Rubtsov YP, Stepanov AV. Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival. Front Mol Biosci. 2021;8:745286. doi: 10.3389/fmolb.2021.745286. PubMed PMID: 34722633; PMCID: PMC8548718.
77. Beider K, Itzhaki O, Schachter J, Grushchenko-Polaq AH, Voevoda-Dimenshtein V, Rosenberg E, Ostrovsky O, Devillers O, Shapira Frommer R, Zeltzer L-A, Toren A, Jacoby E, Shimoni A, Avigdor A, Nagler A, Besser MJ. Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies. Cells [Internet]. 2022 2022/03//; 11 7:[1140 p.]. Available from: http://europepmc.org/abstract/MED/35406703; https://doi.org/10.3390/cells11071140; https://europepmc.org/articles/PMC8997745; https://europepmc.org/articles/PMC8997745?pdf=render; https://mdpi-res.com/d_attachment/cells/cells-11-01140/article_deploy/cells-11-01140-v2.pdf?version=1649644792.